Aripiprazole-Associated Rhabdomyolysis in a 17-Year-Old Male.

Area of Science:

• Neuroscience
• Pharmacology
• Pediatric Medicine

Background:

• Rhabdomyolysis is a rare but serious adverse effect associated with antipsychotic medications.
• Previous reports document rhabdomyolysis linked to clozapine, risperidone, olanzapine, and haloperidol.

Observation:

• A 17-year-old male with somatic symptom disorder developed rhabdomyolysis on day 13 of aripiprazole treatment (2.5 mg/day).
• This represents one of the youngest documented cases of aripiprazole-induced rhabdomyolysis.
• The case is notable for its low-dose, short-term, and monotherapy antipsychotic use.

Findings:

• Aripiprazole, even at low doses and short durations, can precipitate rhabdomyolysis in adolescents.
• Early recognition of nonspecific symptoms is crucial for timely diagnosis and intervention.

Implications:

• Routine baseline blood tests are recommended before initiating antipsychotic medication in children and adolescents.
• Healthcare providers should maintain a high index of suspicion for rhabdomyolysis in pediatric patients on antipsychotics, considering symptoms beyond typical psychiatric complaints.
• This case underscores the need for vigilant monitoring and prompt evaluation of potential adverse drug reactions in young patients receiving antipsychotic therapy.